ID   P815.Trh4
AC   CVCL_C0DF
DR   CancerTools; 157674
DR   Ximbio; 157674
DR   Wikidata; Q114312642
RX   PubMed=29399388;
CC   Transfected with: MGI; MGI:1919199; Cers5.
CC   Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP).
CC   Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Breed/subspecies: DBA/2.
DI   NCIt; C21632; Mouse mast cell neoplasm
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2154 ! P815
SX   Male
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 21-03-23; Version: 3
//
RX   PubMed=29399388; DOI=10.1080/2162402X.2017.1382793;
RA   Doorduijn E.M., Sluijter M., Marijt K.A., Querido B.J.,
RA   van der Burg S.H., van Hall T.;
RT   "T cells specific for a TAP-independent self-peptide remain naive in
RT   tumor-bearing mice and are fully exploitable for therapy.";
RL   OncoImmunology 7:e1382793.1-e1382793.10(2018).
//